| 1. |
- Borrebaeck, Carl, et al.
(author)
-
Progress in miniaturisation of proteon arrays - a step closer to high-density nanoarrays
- 2007
-
In: Drug Discovery Today. - : Elsevier BV. - 1878-5832 .- 1359-6446. ; 12:19-20, s. 813-819
-
Research review (peer-reviewed)abstract
- Protein microarrays is a technology with great promise for high-throughput proteomics. Designing high-performance protein microarrays for global proteome analysis has, however, turned out to be challenging. To this end, major efforts are under way to design novel array formats capable of harboring the tremendous range of probes required to target complex proteomes composed of more than 10 000 analytes. By adopting nanotechnology, the first generation of miniaturized nanoarrays has recently emerged, which opens up new avenues for global proteome analysis and disease proteomics. This review describes the progress and key issues in designing miniaturized protein arrays.
|
|
| 2. |
- Davis, Andrew M., et al.
(author)
-
Limitations and lessons in the use of X-ray structural information in drug design
- 2008
-
In: Drug Discovery Today. - : Elsevier BV. - 1359-6446 .- 1878-5832. ; 13:19-20, s. 831-841
-
Research review (peer-reviewed)abstract
- The use of X-ray crystal structure models continues to provide a strong stimulus to drug discovery, through the direct visualisation of ligand-receptor interactions. There is sometimes a limited appreciation of the uncertainties introduced during the process of deriving an atomic model from the experimentally observed electron density. Here, some of these uncertainties are highlighted with recent examples from the literature, together with snippets of advice for the medicinal chemist embarking on using X-ray crystal structure information in a drug discovery programme.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Tulp, Martin, et al.
(author)
-
Food for thought
- 2006
-
In: Drug Discovery Today. - : Elsevier BV. - 1359-6446 .- 1878-5832. ; 11:23-24, s. 1115-1121
-
Research review (peer-reviewed)abstract
- Do certain kinds of food contain pharmacologically active substances in concentrations that are high enough to have druglike effects when consumed? Are biologically active compounds in food indicative of therapeutic value? Is traditional drug development suitable for testing the merits of food? Is it ethical to test food as a drug on patients? Will dietary disease management remain a pipedream? Is it a fact or fantasy that the Mediterranean diet is beneficial to health? Is a vegetarian diet an elimination therapy, or one of supplementation? What can be learned from animals? Are humans losing the capability of listening to their bodies? In this review, we will address these questions-providing food for thought.
|
|
| 6. |
- Collin, Mattias, et al.
(author)
-
Monitor – biology
- 2005
-
In: Drug Discovery Today. - 1878-5832. ; 10:15, s. 1073-1073
-
Journal article (peer-reviewed)
|
|
| 7. |
- Collin, Mattias, et al.
(author)
-
Monitor – biology
- 2005
-
In: Drug Discovery Today. - 1878-5832. ; 10:1, s. 75-77
-
Journal article (peer-reviewed)
|
|
| 8. |
- Collin, Mattias, et al.
(author)
-
Monitor – biology
- 2005
-
In: Drug Discovery Today. - 1878-5832. ; 10:7, s. 530-531
-
Journal article (peer-reviewed)
|
|
| 9. |
- Collin, Mattias, et al.
(author)
-
Monitor – biology
- 2005
-
In: Drug Discovery Today. - 1878-5832. ; 10:17, s. 1201-1203
-
Journal article (peer-reviewed)
|
|
| 10. |
|
|
